Targeting the Root of Alzheimer’s New ApoE Antibodies Aim to Halt Cognitive Decline

A trio of leading American research institutions have jointly filed a patent for a novel approach to treating Alzheimer’s disease and other forms of dementia – targeting a key protein called ApoE to disrupt the chain of events that leads to brain degeneration. The invention covers antibodies, fusion proteins and genome-editing tools designed to modify how ApoE behaves in the brain, potentially offering one of the most promising new avenues for tackling cognitive decline.

The Problem

Alzheimer’s disease is a relentless neurodegenerative condition responsible for 60 to 70 per cent of all dementia cases. It progresses slowly but steadily, ultimately robbing patients of their memories, identity and independence. Despite decades of research, there are still no treatments capable of stopping or reversing its progression – only a handful of medications that may temporarily ease some symptoms.

At the molecular level, the disease is characterised by the accumulation of amyloid-beta peptides and the formation of neurofibrillary tangles in the brain. A protein called Apolipoprotein E (ApoE) plays a central and troubling role in this process. ApoE exists in three common variants – epsilon 2, epsilon 3 and epsilon 4 – and the epsilon 4 variant is the most significant known genetic risk factor for late-onset Alzheimer’s disease. ApoE influences how amyloid-beta aggregates, spreads and is cleared from the brain, and it also worsens tau-driven neurodegeneration.

One of the key mechanisms driving this harmful activity involves ApoE binding to heparan sulfate proteoglycans (HSPGs) – molecules on cell surfaces and in the surrounding tissue matrix. This binding interaction influences the seeding and spread of amyloid plaques. Disrupting or modulating this specific binding affinity could, in theory, interrupt the disease process at a fundamental level – but until now, doing so in a targeted, therapeutic way has remained elusive.

What This Invention Does

The inventors have developed a suite of molecular tools – including antibodies, peptides, fusion proteins and genome-editing systems – specifically designed to modulate the binding between ApoE and HSPGs. By altering the HSPG/heparin-binding affinity of ApoE, these tools can potentially reduce amyloid plaque formation, slow neurodegeneration and preserve cognitive function.

The antibodies described in the patent are designed to bind to specific regions of ApoE and either block or alter its interaction with HSPGs. Fusion proteins combine portions of ApoE with other functional domains to redirect or dampen its harmful activity. In addition, the patent covers diagnostic methods – including genetic tests – that could identify patients most at risk or most likely to respond to treatment, supporting a personalised medicine approach.

Importantly, the research underpinning this patent has benefited from significant US federal government funding, including grants from the National Institutes of Health, the National Institute on Aging and the National Institute of Neurological Disorders and Stroke – indicating the scientific weight and credibility behind these discoveries.

Key Features

ApoE-targeting antibodies. Novel antibodies that bind to specific domains of the ApoE protein, modulating its interaction with heparan sulfate proteoglycans to reduce amyloid aggregation and plaque formation in the brain.

Fusion protein compositions. Engineered fusion proteins that combine ApoE-binding regions with other functional domains, offering multiple mechanisms for modulating the disease pathway and potentially enhancing therapeutic activity.

Genome editing applications. The invention extends to genome-editing systems that could modify how ApoE is expressed or structured, opening the door to potentially durable, long-lasting interventions.

Diagnostic companion methods. Genetic testing and biomarker methods are covered, enabling identification of at-risk patients and supporting precision medicine approaches to Alzheimer’s treatment.

Multi-target approach. By addressing both amyloid-beta and tau pathways through ApoE modulation, the invention potentially targets the disease more broadly than treatments focused on a single molecular pathway.

Who Is Behind It?

This application is a divisional of earlier application AU 2020282792, tracing its origins back to US provisional applications filed in May and July 2019. It is a collaboration between three major US research institutions: Banner Health, a large non-profit health system in Phoenix, Arizona, with a prominent Alzheimer’s disease research programme; The General Hospital Corporation, the research arm of Massachusetts General Hospital in Boston; and The Schepens Eye Research Institute, an affiliate of Harvard Medical School. The inventors include Yakeel T. Quiroz, Joseph F. Arboleda-Velasquez, Eric M. Reiman and Francisco Lopera – a team spanning neurology, ophthalmology and Alzheimer’s genetics.

Why It Matters

Alzheimer’s disease affects tens of millions of people worldwide, and its prevalence is expected to grow dramatically as populations age. The enormous personal, social and economic costs make the search for effective treatments one of the most urgent challenges in modern medicine. An intervention that could genuinely slow or stop cognitive decline – rather than merely manage symptoms – would be transformative for patients, carers and health systems globally.

The ApoE-HSPG axis represents a relatively underexplored but scientifically compelling target. The involvement of multiple world-class research institutions, federal government research funding and the breadth of molecular approaches covered by this patent suggest a serious, well-resourced programme that could yield clinically meaningful results. With IPC classifications spanning biochemistry (C07K), neurology (A61P 25/28) and diagnostic genomics (C12Q 1/6883), the invention sits at the intersection of drug development and precision diagnostics.

---

AU 2026201500 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Apolipoprotein E (ApoE) is a lipid-transport protein whose epsilon 4 variant is the strongest known genetic risk factor for late-onset Alzheimer’s disease. Its interaction with heparan sulfate proteoglycans on cell surfaces influences how amyloid-beta plaques seed and spread, making this binding axis a compelling molecular target for therapies that aim to slow or prevent neurodegeneration at its source.